Cannabis and Migraine
What the evidence actually shows about using cannabis for migraine prevention and acute attacks, separated from marketing claims.
Cannabis is one of the oldest documented migraine remedies, and a lot of patients say it helps. But the modern evidence is mostly surveys and observational studies — not the randomized trials that would let a neurologist confidently recommend it. There's a real risk that frequent use causes medication-overuse headache or, paradoxically, cannabinoid hyperemesis. Treat it as a plausible adjunct worth discussing with a headache specialist, not a proven first-line treatment.
Not Medical Advice
This article is not medical advice. It is a plain-language summary of published evidence. Migraine has many subtypes and overlaps with conditions (stroke, intracranial hypertension, medication overuse) that require diagnosis by a clinician. If you have new, severe, or changing headaches, see a doctor. If you are considering cannabis for migraine, discuss it with a neurologist or headache specialist, especially if you take triptans, SSRIs/SNRIs, or anticoagulants.
Plain-Language Summary
Migraine is a neurological disorder, not just a bad headache. Cannabis has been used for migraine for at least 150 years — Sir William Osler called Indian hemp "probably the most satisfactory remedy" for migraine in his 1892 textbook [1]. Modern research is much thinner than that history suggests.
What we have in 2024:
- A handful of small observational studies and patient surveys suggesting inhaled cannabis reduces acute migraine pain intensity Weak / limited [2][3].
- One small randomized crossover trial (Nabilone vs. ibuprofen for medication-overuse headache) showing benefit Weak / limited [4].
- No large, high-quality randomized controlled trials for migraine prevention.
- Documented risk of medication-overuse headache with frequent use Strong evidence [5].
The American Headache Society and American Academy of Neurology do not include cannabis in their evidence-based treatment guidelines [6]. That's not because it's been proven not to work — it's because it hasn't been adequately tested.
What Probably Works
Honestly, nothing about cannabis for migraine reaches "probably works" by the standards we'd apply to a pharmaceutical. The closest claim with the most consistent signal:
Inhaled THC-dominant cannabis reduces self-reported acute headache/migraine pain intensity in the short term. A 2019 Washington State University study analyzed 12,293 sessions logged in the Strainprint app and found ~50% reduction in self-rated headache severity, with diminishing returns over time Weak / limited [2]. This is observational, unblinded, and selection-biased (people who don't get relief stop logging), so it shouldn't be confused with proof of efficacy. But it's the largest dataset we have and it points the same direction as smaller surveys [3].
What Might Work
Nabilone (synthetic THC) for medication-overuse headache. A 2012 double-blind crossover trial in 30 patients found nabilone 0.5 mg outperformed ibuprofen 400 mg on pain intensity and analgesic dependence Weak / limited [4]. Single small trial, needs replication.
THC:CBD combinations for migraine prevention. A 2017 conference presentation (Italian study, not full peer-reviewed publication) reported a 200 mg/day THC:CBD combination reduced migraine frequency comparably to amitriptyline Weak / limited. Often cited but never published as a full paper, which is a real limitation — we include it because it's frequently referenced, not because it's solid.
CBD alone. Despite heavy marketing, there is essentially no controlled trial data on isolated CBD for migraine No data. Mechanistic plausibility exists (anti-inflammatory, possible effects on CGRP signaling), but plausibility is not evidence.
What Doesn't Work or Has Weak Evidence
"Indica vs. sativa" for migraine relief. Folklore. The indica/sativa dichotomy doesn't reliably predict chemical composition or effects Disputed. See Indica vs Sativa.
Specific "migraine strains." Dispensary recommendations for cultivars like Harlequin, ACDC, or OG Kush for migraine are based on customer reports, not controlled trials Anecdote.
Topical CBD for migraine. No meaningful evidence No data. Migraine is a central nervous system event; transdermal CBD doesn't reach therapeutic plasma levels.
The "endocannabinoid deficiency" hypothesis as established cause. Ethan Russo proposed clinical endocannabinoid deficiency (CECD) as a possible mechanism in migraine, fibromyalgia, and IBS [7]. It's an interesting hypothesis with some supporting findings (lower anandamide in CSF of chronic migraineurs), but it remains a hypothesis, not established fact Weak / limited.
What We Don't Know
- Optimal dose, cannabinoid ratio, or route of administration.
- Whether cannabis prevents migraines or only treats attacks.
- Long-term efficacy (tolerance is a real concern — see Cannabis Tolerance).
- Whether CBD alone has any migraine-specific effect.
- Interactions with CGRP monoclonal antibodies (erenumab, fremanezumab) — these are the newest preventive class and have not been studied with co-administered cannabis.
- Whether benefits in observational studies will survive a properly blinded RCT. Cannabis has notoriously strong placebo effects because the psychoactive experience is itself an active blind-breaker.
Comparison With Standard Treatments
Evidence-based migraine treatments with strong RCT support [6]:
Acute: Triptans (sumatriptan, rizatriptan, etc.), gepants (rimegepant, ubrogepant), ditans (lasmiditan), NSAIDs, and antiemetics. Triptans are the gold standard for moderate-to-severe attacks and work in ~60-70% of patients Strong evidence.
Preventive: CGRP monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab), topiramate, propranolol, amitriptyline, onabotulinumtoxinA for chronic migraine Strong evidence.
Cannabis has not been compared head-to-head with any of these in adequately powered trials. A reasonable framing: if standard treatments work for you, there's no strong reason to switch. If they don't, or you can't tolerate them, cannabis is one of several adjuncts to discuss with a specialist — alongside nerve blocks, neuromodulation devices, and supplements like riboflavin and magnesium that also have weak-to-moderate evidence.
Risks
Medication-overuse headache (MOH). Any acute migraine treatment used >10-15 days/month can cause MOH. Cannabis is no exception — a 2018 study found cannabis users with chronic migraine had higher MOH rates Strong evidence [5].
Cannabinoid hyperemesis syndrome (CHS). Cyclic vomiting in heavy long-term users. Easily misdiagnosed as migraine with vomiting, and the treatment (stop cannabis) is the opposite. See Cannabinoid Hyperemesis Syndrome Strong evidence.
Drug interactions. THC and CBD inhibit CYP450 enzymes. Clinically relevant interactions exist with some antidepressants and anticonvulsants used for migraine prophylaxis Strong evidence [8].
Cardiovascular. Migraine with aura already carries elevated stroke risk; cannabis use is associated with increased risk of ischemic stroke in young adults [evidence:weak-to-moderate] [9].
Cognitive and occupational. Daily THC use affects attention and memory. For people whose migraines are already disabling, adding cognitive impairment may not be a good trade.
Pregnancy. Avoid. Cannabis use in pregnancy is associated with adverse outcomes and no migraine treatment in pregnancy should be self-initiated Strong evidence [10].
Bottom Line
Cannabis for migraine is plausible, has a long historical track record, has consistent positive signals in observational data, and lacks the randomized trials that would make it a guideline-recommended treatment. If standard therapies are failing you, it's a reasonable conversation to have with a headache specialist — particularly one who won't dismiss it out of hand and won't oversell it either. Be especially cautious about daily use, which can flip from helping to causing headaches without you noticing.
Sources
- Book Osler W, McCrae T. The Principles and Practice of Medicine. D. Appleton and Company; 1892.
- Peer-reviewed Cuttler C, Spradlin A, Cleveland MJ, Craft RM. Short- and long-term effects of cannabis on headache and migraine. Journal of Pain. 2020;21(5-6):722-730.
- Peer-reviewed Rhyne DN, Anderson SL, Gedde M, Borgelt LM. Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacotherapy. 2016;36(5):505-510.
- Peer-reviewed Pini LA, Guerzoni S, Cainazzo MM, et al. Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. Journal of Headache and Pain. 2012;13(8):677-684.
- Peer-reviewed Zhang N, Woldeamanuel YW. Medication overuse headache in patients with chronic migraine using cannabis: a case-referent study. Headache. 2021;61(8):1234-1244.
- Peer-reviewed Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-1039.
- Peer-reviewed Russo EB. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and Cannabinoid Research. 2016;1(1):154-165.
- Peer-reviewed Alsherbiny MA, Li CG. Medicinal cannabis—potential drug interactions. Medicines. 2018;6(1):3.
- Peer-reviewed Hemachandra D, McKetin R, Cherbuin N, Anstey KJ. Heavy cannabis users at elevated risk of stroke: evidence from a general population survey. Australian and New Zealand Journal of Public Health. 2016;40(3):226-230.
- Government American College of Obstetricians and Gynecologists Committee Opinion No. 722: Marijuana use during pregnancy and lactation. Obstet Gynecol. 2017;130(4):e205-e209.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Chronic Pain — What the evidence actually says about cannabis for long-term pain, separated from the mark...